308 related articles for article (PubMed ID: 31126963)
21. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
22. Immune thrombocytopenia in adults: an update.
Thota S; Kistangari G; Daw H; Spiro T
Cleve Clin J Med; 2012 Sep; 79(9):641-50. PubMed ID: 22949345
[TBL] [Abstract][Full Text] [Related]
23. Rituximab salvage therapy in adults with immune thrombocytopenia: retrospective study on efficacy and safety profiles.
Reboursiere E; Fouques H; Maigne G; Johnson H; Chantepie S; Gac AC; Reman O; Macro M; Benabed K; Troussard X; Damaj G; Cheze S
Int J Hematol; 2016 Jul; 104(1):85-91. PubMed ID: 27040278
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab.
Chemnitz JM; Uener J; Hallek M; Scheid C
Ann Hematol; 2010 Oct; 89(10):1029-33. PubMed ID: 20422413
[TBL] [Abstract][Full Text] [Related]
25. Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients.
Zwaginga JJ; van der Holt B; Te Boekhorst PA; Biemond BJ; Levin MD; van der Griend R; Brand A; Zweegman S; Pruijt HF; Novotny VM; Vreugdenhil A; de Groot MR; de Weerdt O; van Pampus EC; van Maanen-Lamme TM; Wittebol S; Schipperus MR; Silbermann MH; Huijgens PC; Luten M; Hollestein R; Brakenhoff JA; Schrama JG; Valster FA; Velders GA; Koene HR;
Haematologica; 2015 Mar; 100(3):e90-2. PubMed ID: 25425692
[No Abstract] [Full Text] [Related]
26. [Efficiency and good tolerance of rituximab for idiopathic thrombocytopenic purpura revealing a 22q11 deletion syndrome].
Vautier M; Georgin-Lavialle S; Hermine O; Bienvenu B; Lacaze E; Gerard M; Aouba A
Rev Med Interne; 2016 Nov; 37(11):766-770. PubMed ID: 26869291
[TBL] [Abstract][Full Text] [Related]
27. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
[TBL] [Abstract][Full Text] [Related]
28. ITP Is Neither Idiopathic nor Always Benign.
Konda M; Fletcher M; Warrier R
Clin Pediatr (Phila); 2021 Mar; 60(3):193-194. PubMed ID: 33305594
[No Abstract] [Full Text] [Related]
29. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment.
Chang H; Tang TC; Hung YS; Li PL; Kuo MC; Wu JH; Wang PN
Eur J Haematol; 2018 Oct; 101(4):549-555. PubMed ID: 30007087
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of refractory immune thrombocytopenia with rituximab in a 10-week-old infant.
Gray C; Kalumba K; Pati N; Peterson A; Connell TG
J Pediatr Hematol Oncol; 2013 May; 35(4):e174-7. PubMed ID: 23459375
[TBL] [Abstract][Full Text] [Related]
31. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
32. [Severe corticoid-refractory autoimmune thrombocytopenia associated with mixed connective tissue disease (Sharp's syndrome). Treatment with rituximab].
Rudolph SE; Kouba M; Hrdlicka P
Dtsch Med Wochenschr; 2009 Sep; 134(36):1734-8. PubMed ID: 19718594
[TBL] [Abstract][Full Text] [Related]
33. Use of rituximab in refractory autoimmune thrombocytopenia following an autologous stem cell transplant.
Price S; Cumpston A; Altaha R
Hematology; 2006 Feb; 11(1):43-4. PubMed ID: 16522548
[TBL] [Abstract][Full Text] [Related]
34. [Treatment of immune thrombocytopenia: a retrospective study of 40 patients].
Audia S; Lakomy D; Guy J; Leguy-Seguin V; Berthier S; Aho S; Lorcerie B; Bonnotte B
Rev Med Interne; 2010 May; 31(5):337-44. PubMed ID: 20409619
[TBL] [Abstract][Full Text] [Related]
35. Second-line and beyond: treatment options for primary persistent and chronic immune thrombocytopenia.
Deshayes S; Godeau B
Platelets; 2020; 31(3):291-299. PubMed ID: 31272259
[TBL] [Abstract][Full Text] [Related]
36. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux.
Deshayes S; Khellaf M; Zarour A; Layese R; Fain O; Terriou L; Viallard JF; Cheze S; Graveleau J; Slama B; Audia S; Cliquennois M; Ebbo M; Le Guenno G; Salles G; Bonmati C; Teillet F; Galicier L; Lambotte O; Hot A; Lefrère F; Mahévas M; Canoui-Poitrine F; Michel M; Godeau B
Am J Hematol; 2019 Dec; 94(12):1314-1324. PubMed ID: 31489694
[TBL] [Abstract][Full Text] [Related]
37. How I treat refractory immune thrombocytopenia.
Cuker A; Neunert CE
Blood; 2016 Sep; 128(12):1547-54. PubMed ID: 27053529
[TBL] [Abstract][Full Text] [Related]
38. [Rituximab for treatment of immune thrombocytopenia and thrombotic thrombocytopenic purpura].
Miyakawa Y
Rinsho Ketsueki; 2019; 60(5):480-487. PubMed ID: 31168017
[TBL] [Abstract][Full Text] [Related]
39. [Cost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in France].
Chiche L; Perrin A; Stern L; Kutikova L; Cohen-Nizard S; Lefrère F
Transfus Clin Biol; 2014 May; 21(2):85-93. PubMed ID: 24797790
[TBL] [Abstract][Full Text] [Related]
40. Rituximab is effective in the treatment of refractory immune thrombocytopenic purpura associated with chronic lymphocytic leukemia.
Oo TH
South Med J; 2005 Dec; 98(12):1227-8. PubMed ID: 16440930
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
